Salazosulfapyridine-induced angioimmunoblastic lymphadenopathy

Intern Med. 1996 Nov;35(11):894-7. doi: 10.2169/internalmedicine.35.894.

Abstract

A 20-year-old man with ulcerative colitis was admitted because of fever, eruption and lymphadenopathy. He had started taking salazosulfapyridine one month previously. Lymph node biopsy revealed angioimmunoblastic lymphadenopathy. Autoantibody titers were all negative, and viral antibody titers were not increased retrospectively. Rearrangement of T-cell receptor beta and chromosomal aberration were not seen on the lymph node. This case is considered not to be a peripheral T-cell lymphoma but rather salazosulfapyridine-induced angioimmunoblastic lymphadenopathy (AIL), which is the second case in English language literature.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / adverse effects*
  • Anti-Inflammatory Agents / therapeutic use
  • Colitis, Ulcerative / drug therapy
  • Gastrointestinal Agents / adverse effects*
  • Humans
  • Immunoblastic Lymphadenopathy / chemically induced*
  • Immunoblastic Lymphadenopathy / drug therapy
  • Immunoblastic Lymphadenopathy / pathology
  • Male
  • Methylprednisolone / therapeutic use
  • Prednisolone / therapeutic use
  • Sulfasalazine / adverse effects*

Substances

  • Anti-Inflammatory Agents
  • Gastrointestinal Agents
  • Sulfasalazine
  • Prednisolone
  • Methylprednisolone